{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:38:44Z","timestamp":1794285524605,"version":"4.9.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008140","name":"The University of Chicago Pritzker School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008140","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jpsychires.2025.03.056","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T07:27:42Z","timestamp":1743406062000},"page":"112-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comparing efficacy of serotonergic, opioidergic, and glutamatergic drugs in gambling disorder: A pooled analysis of response trajectories versus placebo"],"prefix":"10.1016","volume":"185","author":[{"given":"Mauro","family":"Pettorruso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-4064","authenticated-orcid":false,"given":"Giorgio","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Gelormini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-6005","authenticated-orcid":false,"given":"Roberto","family":"Guidotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7784-7021","authenticated-orcid":false,"given":"Jon E.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2025.03.056_bib1","article-title":"Emerging gambling problems and suggested interventions: a systematic review of empirical research","author":"Ak\u00e7ay\u0131r","year":"2023","journal-title":"J. Gambl. Stud."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2021.107127","article-title":"Intranasal as needed naloxone in the treatment of gambling disorder: a randomised controlled trial","volume":"125","author":"Alho","year":"2022","journal-title":"Addict. Behav."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/npp.2010.226","article-title":"Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans","volume":"36","author":"Amen","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.comppsych.2023.152435","article-title":"Cluster analysis in gambling disorder based on sociodemographic, neuropsychological, and neuroendocrine features regulating energy homeostasis","volume":"128","author":"Baenas","year":"2024","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/15622975.2011.560964","article-title":"A double-blind, placebo-controlled trial of topiramate for pathological gambling","volume":"14","author":"Berlin","year":"2013","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/add.15952","article-title":"Global prevalence of help-seeking for problem gambling: a systematic review and meta-analysis","author":"Bijker","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.jcp.0000264985.25109.25","article-title":"Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study","volume":"27","author":"Black","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib8","article-title":"An open-label trial of acamprosate in the treatment of pathological gambling","volume":"23","author":"Black","year":"2011","journal-title":"Ann. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/npp.1994.53","article-title":"Placebo as a treatment for depression","volume":"10","author":"Brown","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10899-016-9620-z","article-title":"Topiramate combined with cognitive restructuring for the treatment of gambling disorder: a two-center, randomized, double-blind clinical trial","volume":"33","author":"de Brito","year":"2017","journal-title":"J. Gambl. Stud."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s10899-024-10311-9","article-title":"Linking striatal dopaminergic asymmetry with personality traits: insights from gambling disorder","author":"Di Carlo","year":"2024","journal-title":"J. Gambl. Stud."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib12","article-title":"Pharmacological interventions for the treatment of disordered and problem gambling","author":"Dowling","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pbb.2007.12.025","article-title":"A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers","volume":"89","author":"Fong","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2022.114089","article-title":"N-acetylcysteine improves impulse control and attenuates relapse-like alcohol intake in long-term drinking rats","volume":"436","author":"Fredriksson","year":"2023","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jamapsychiatry.2022.1970","article-title":"Neuropsychoimaging measures as alternatives to drug use outcomes in clinical trials for addiction","volume":"79","author":"Goldstein","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib16","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1556\/2006.7.2018.93","article-title":"Clustering of treatment-seeking women with gambling disorder","volume":"7","author":"Granero","year":"2018","journal-title":"J. Behav. Addict."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib17","first-page":"167","article-title":"The placebo effect and its clinical associations in gambling disorder","volume":"29","author":"Grant","year":"2017","journal-title":"Ann. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-010-1994-5","article-title":"Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study","volume":"212","author":"Grant","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-008-1235-3","article-title":"Predicting response to opiate antagonists and placebo in the treatment of pathological gambling","volume":"200","author":"Grant","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2008.11.022","article-title":"A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania","volume":"65","author":"Grant","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.biopsych.2006.11.021","article-title":"N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study","volume":"62","author":"Grant","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.yic.0000073881.93678.21","article-title":"Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial","volume":"18","author":"Grant","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib23","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.euroneuro.2013.07.008","article-title":"A proof of concept study of tolcapone for pathological gambling: relationships with COMT genotype and brain activation","volume":"23","author":"Grant","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4088\/JCP.13m08411","article-title":"A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers","volume":"75","author":"Grant","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1192\/bjp.bp.110.078105","article-title":"Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study","volume":"197","author":"Grant","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/00004850-200607000-00002","article-title":"Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation","volume":"21","author":"Grant","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.163.2.303","article-title":"Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling","volume":"163","author":"Grant","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4088\/JCP.v69n0511","article-title":"A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges","volume":"69","author":"Grant","year":"2008","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib29","series-title":"ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW Publication No. ADM 76\u2013338)","author":"Guy","year":"1976"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib30","doi-asserted-by":"crossref","DOI":"10.1176\/ajp.155.12.1781","article-title":"Short-term single-blind fluvoxamine treatment of pathological gambling","volume":"155","author":"Hollander","year":"1998","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jpsychires.2021.09.053","article-title":"Diverse predictors of treatment response to active medication and placebo in gambling disorder","volume":"144","author":"Huneke","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2022.105968","article-title":"The influence of opioid blockage on the sexual response cycle: a randomized placebo-controlled experiment with relevance for the treatment of Compulsive Sexual Behavior Disorder (CSBD)","volume":"147","author":"Incoronato","year":"2023","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.110942","article-title":"N-acetylcysteine attenuates accumbal core neuronal activity in response to morphine in the reinstatement of morphine CPP in morphine extinguished rats","volume":"131","author":"Katebi","year":"2024","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4088\/JCP.v63n0606","article-title":"A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling","volume":"63","author":"Kim","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0006-3223(01)01079-4","article-title":"Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling","volume":"49","author":"Kim","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib36","article-title":"A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling","volume":"22","author":"Kovanen","year":"2016","journal-title":"Eur. Addctn. Res."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/14656566.2019.1702969","article-title":"Current pharmacotherapy for gambling disorder: a systematic review","author":"Kraus","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib38","article-title":"Understanding gambling related harm: a proposed definition, conceptual framework, and taxonomy of harms","volume":"16","author":"Langham","year":"2016","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib39","doi-asserted-by":"crossref","DOI":"10.1176\/ajp.2007.164.7.1115","article-title":"Is cocaine desire reduced by N-acetylcysteine?","volume":"164","author":"Larowe","year":"2007","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/0306-4522(84)90048-4","article-title":"Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine","volume":"11","author":"Matthews","year":"1984","journal-title":"Neuroscience"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4088\/JCP.v69n0314","article-title":"Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial","volume":"69","author":"McElroy","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib42","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.23-08-03531.2003","article-title":"Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior","volume":"23","author":"McFarland","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib43","article-title":"Roles for alexithymia, emotion dysregulation and personality features in gambling disorder: a network analysis","volume":"39","author":"Mestre-Bach","year":"2023","journal-title":"J. Gambl. Stud."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib44","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/14737175.2024.2316833","article-title":"Pharmacological management of gambling disorder: an update of the literature","volume":"24","author":"Mestre-Bach","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib45","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/add.15745","article-title":"Clarifying gambling subtypes: the revised pathways model of problem gambling","volume":"117","author":"Nower","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/109786","article-title":"Targeting the glutamatergic system to treat pathological gambling: current evidence and future perspectives","author":"Pettorruso","year":"2014","journal-title":"Biomed. Res. Int. 2014"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib47","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14656566.2023.2172329","article-title":"The pharmacological management of gambling disorder: if, when, and how","volume":"24","author":"Pettorruso","year":"2023","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-024-02423-w","article-title":"Addiction biotypes: a paradigm shift for future treatment strategies?","author":"Pettorruso","year":"2024","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2020.106813","article-title":"The transition time to gambling disorder: the roles that age, gambling preference and personality traits play","volume":"116","author":"Pettorruso","year":"2021","journal-title":"Addict. Behav."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neubiorev.2020.09.034","article-title":"Exploring dopaminergic transmission in gambling addiction: a systematic translational review","volume":"119","author":"Pettorruso","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0099-7","article-title":"Gambling disorder","volume":"5","author":"Potenza","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib52","series-title":"R: A Language and Environment for Statistical Computing","year":"2021"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib53","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.17-21-08491.1997","article-title":"Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine","volume":"17","author":"Robinson","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib54","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v66n0104","article-title":"Sertraline treatment of pathological gambling: a pilot study","volume":"66","author":"Saiz-Ruiz","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib55","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1038\/npp.2012.66","article-title":"N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study","volume":"37","author":"Schmaal","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib56","article-title":"Opioid antagonists for pharmacological treatment of gambling disorder: are they relevant?","volume":"16","author":"Victorri-Vigneau","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib57","doi-asserted-by":"crossref","DOI":"10.1111\/j.1360-0443.2005.01341.x","article-title":"A framework for reporting outcomes in problem gambling treatment research: the Banff, Alberta Consensus","volume":"101","author":"Walker","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.jpsychires.2025.03.056_bib58","doi-asserted-by":"crossref","DOI":"10.1556\/2006.7.2018.89","article-title":"The use of naltrexone in pathological and problem gambling: a UK case series","volume":"7","author":"Ward","year":"2018","journal-title":"J. Behav. Addict."},{"key":"10.1016\/j.jpsychires.2025.03.056_bib59","article-title":"An open-label study of citalopram in the treatment of pathological gambling","volume":"4","author":"Zimmerman","year":"2002","journal-title":"Prim. Care Companion J. Clin. Psychiatry"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625002109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625002109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:44:56Z","timestamp":1745628296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395625002109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":59,"alternative-id":["S0022395625002109"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.03.056","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing efficacy of serotonergic, opioidergic, and glutamatergic drugs in gambling disorder: A pooled analysis of response trajectories versus placebo","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.03.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}